×

Kidney Cancer Drugs Market Expected to Reach USD 4.5 Billion Globally by 2020, growing at a CAGR of 6.6% from 2014 to 2020 : Transparency Market Research

Albany, NY, March 30, 2015 (GLOBE NEWSWIRE) -- According to a new market report published by Transparency Market Research "Kidney Cancer Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020", the global kidney cancer drugs market was valued at USD 2.6 billion in 2013 and is expected to reach USD 4.5 billion in 2020, growing at a CAGR of 6.6% from 2014 to 2020.

Browse Full Market Research of Kidney Cancer Drugs Market: http://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html

Kidney cancer or renal cell carcinoma (RCC) is one of the common urologic tumors accounting for around 3% of all human malignancies. The incidence rate of renal cell carcinoma has increased progressively in the recent decades. According to the American Cancer Society, about 61,500 newly diagnosed cases are expected to occur in the U.S. in 2015. Kidney cancer rates are expected to increase every year with reduction in physical activity, rise in obesity and smoking, etc., which leads to an unhealthy lifestyle and increased susceptibility to cancer. The global incidence of kidney cancer diagnosis has reportedly increased by 10% to 30% every decade since 1999. Thus, high incidence and prevalence rates of kidney cancer have helped this market to transform it into billion-dollar market.

Get Sample Report Copy OR For further inquiries, click here: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=537

The global kidney cancer drugs market has been segmented based on the major branded drugs generally prescribed and used for the treatment of various types of kidney cancer such as Sutent (Sunitinib), Nexavar (Sorafenib), Afinitor (Everolimus), Votrient (Pazopanib), Inlyta (Axitinib), Avastin (Bevacizumab), Torisel (Temsirolimus) and Proleukin (Aldesleukin). In terms of revenue, Sutent accounted for the largest share of over 30% of the kidney cancer drugs market in 2013. However, the drug is expected to grow at a sluggish CAGR of 1.1% from 2012 to 2016 and a CAGR of 2.1% from 2016 to 2020. Sunitinib is a well-known drug and often used as the first-line treatment for RCC. Sunitinib is among the most studied drugs in its class for multiple indications, as it targets multiple receptor tyrosine kinases (RTKs). However, the relatively high price of the drug has often been regarded as a serious drawback to the use of Sutent, although the drug has been considered the first-line treatment agent for RCC. Moreover, in terms of market growth Votrient is expected to witness the highest growth rate among all kidney cancer drugs during the forecast period. The drug is expected to witness a CAGR of 41.7% from 2012 to 2016 and a CAGR of 8.9% from 2016 to 2020. However, with the loss of patent exclusivity, generic drug variants would offer clinicians a broad range of affordable medications to prescribe, thereby significantly reducing the overall size of the kidney cancer drugs market to an extent. Hence, commercialization of novel molecules for treating diverse kidney cancers including renal cell carcinoma would govern the future market growth of the kidney cancer drugs market.

Browse Press Release of Kidney Cancer Drugs Market: http://www.transparencymarketresearch.com/pressrelease/kidney-cancer-drugs-market.htm

Potential pipeline drugs identified and expected to be launched during the forecast period from 2014 to 2020 include Dovitinib [(TKI258) (Novartis AG)], Opdivo [(Nivolumab) (Bristol-Myers Squibb)], AGS-003 (Argos Therapeutics, Inc.), Cabozantinib [(XL184) (Exelixis, Inc.)] and Keytruda [(Anti PD 1) (Merck & Co., Inc.)]. Successful clinical trial outcomes of these molecules such as improved efficacy, with shorter onset of action and fewer side effects as well as expected commercialization during the forecast period are predicted to stimulate the growth of kidney cancer drugs market in the near future.

Geographically, North America accounted for the largest revenue share of kidney cancer drugs in 2013 (over 45%). The fact that the U.S. is the largest pharmaceutical market globally, accounting for a share of 90% of the market in North America, substantiates the dominance of the region in the global market. The U.S. accounts for the highest share of the revenue for each drug used for the treatment of kidney cancer. Canada accounts for the remaining 10% market share in North America. This leading position of the North American region in the kidney cancer drugs market is due to the presence of one or more branded formulations that influence the market dynamics significantly. The region also continues to dominate the market due to the high prevalence of kidney cancer. Hence, North America is expected to witness an appreciable growth rate throughout the forecast period from 2014 to 2020. Asia Pacific is expected to experience the highest growth rate (over 6%) owing to various factors such as growing elderly population and existence of a large population base susceptible to kidney cancer. Additionally, strong economic growth in countries such as China, Japan, New Zealand and Australia would contribute to the growth of the market in Asia Pacific.

Browse Article on Kidney Cancer Drugs Market: http://www.transparencymarketresearch.com/article/kidney-cancer-drugs-market.htm

The market exhibits intense competition among existing players, as currently the market for kidney cancer drugs is highly consolidated, comprising a few established pharmaceutical giants. Major market players include Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG and Pfizer, Inc. Pfizer, Inc. held the largest share of over 40% of the total kidney cancer drugs market in 2013. Product differentiation, safety, distribution networks and supply capabilities play a major role in determining the market position of the company and other market players.

Other Reports By Transparency Market Research :

The Global Kidney Cancer Drugs Market is segmented as follows:

Kidney Cancer Drugs Market, by Major Branded Drugs

  • Sutent (Sunitinib)
  • Nexavar (Sorafenib)
  • Afinitor (Everolimus)
  • Votrient (Pazopanib)
  • Inlyta (Axitinib)
  • Avastin (Bevacizumab)
  • Torisel (Temsirolimus)
  • Proleukin (Aldesleukin)

Kidney Cancer Drugs Market, by Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World (RoW)

Browse All Pharmaceutical Market Research Reports: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us :

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

CONTACT: Mr. Nachiket Ghumare State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/

Source:Transparency Market Research